Biotech company AAX Biotech, which specializes in innovative technologies for improving antibody-based medicines, is thrilled to announce that BioArctic AB, a renowned Swedish biopharma company focused on neurodegenerative diseases, has decided to use AAX Biotech’s proprietary epitope mapping technology, Seqitope™.
AAX Biotech is committed to addressing unmet demands in the advancement of next-generation antibody therapeutics. The company’s two pioneering technologies, Seqitope™ and Opti-mAb™, improve the performance and developability of antibody-based therapeutics and offer a unique solution in a rapidly growing market. This milestone marks a significant achievement for AAX Biotech, highlighting the company’s role in advancing research with its Seqitope™ technology—a high-resolution, high-throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics.
“Having BioArctic use our technology represents a unique opportunity for AAX Biotech to contribute to the fight against neurodegenerative diseases which affect millions of persons worldwide,” says Maria L. Knudsen, CEO of AAX Biotech. “We are fully committed to this challenging project and are eager to apply our technology to support BioArctic.”
For more information about AAX Biotech AB and its products or services, please contact: Maria Lisa Knudsen at +46 72 939 5018 or visit www.aaxbiotech.com.
About AAX Biotech AB:
AAX Biotech AB is a biotechnology company based in Stockholm, Sweden that specializes in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope™ and Opti-mAb™, which enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. Founded by experts from Karolinska Institutet in Stockholm